IN8bio, Inc.
NASDAQ Global MarketTotal Valuation
IN8bio, Inc. carries a market capitalization of 11.41M, placing it among publicly traded companies globally. Its enterprise value stands at -1.89M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 11.41M |
| Enterprise Value | -1.89M |
Share Statistics
IN8bio, Inc. currently has 9.85M shares outstanding.
| Shares Outstanding | 9.85M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.76 |
| P/TBV Ratio | 0.76 |
| P/FCF Ratio | -1.45 |
| P/OCF Ratio | -1.42 |
Financial Position
IN8bio, Inc. maintains a current ratio of 8.21, meaning it holds 8.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 8.21 |
| Quick Ratio | 7.97 |
| Debt / Equity | 11.86 |
| Debt / EBITDA | -0.13 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -111.11 |
| Return on Assets (ROA) | -90.80 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
IN8bio, Inc.'s stock has declined approximately -43.0622% over the past 52 weeks. The 50-day moving average sits at 1.12, while the 200-day moving average is 1.56.
| Beta (5Y) | N/A |
| 52-Week Price Change | -43.0622% |
| 50-Day Moving Average | 1.12 |
| 200-Day Moving Average | 1.56 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -17.20M, while operating income came in at -19.20M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -19.20M |
| Pretax Income | -18.67M |
| Net Income | -18.67M |
| EBITDA | -17.20M |
| EBIT | -19.20M |
| Earnings Per Share (EPS) | -1.29 |
Balance Sheet
IN8bio, Inc. holds 17.96M in cash and equivalents against 2.18M in total debt, resulting in a net debt position of -17.96M. Total book value stands at 18.36M, with working capital of 16.24M providing operational flexibility.
| Cash & Cash Equivalents | 17.96M |
| Total Debt | 2.18M |
| Net Debt | -17.96M |
| Equity (Book Value) | 18.36M |
| Book Value Per Share | 1.86 |
| Working Capital | 16.24M |
Cash Flow
IN8bio, Inc. produced -14.35M in operating cash flow over the past twelve months. After subtracting -242,000.00 in capital expenditures, free cash flow totaled -14.60M - equivalent to -1.01 per share.
| Operating Cash Flow | -14.35M |
| Capital Expenditures | -242,000.00 |
| Free Cash Flow | -14.60M |
| FCF Per Share | -1.01 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -138.52 |
| FCF Yield | -69.07 |
Stock Splits
IN8bio, Inc.'s most recent stock split took place on June 6, 2025 with a 30:1 split ratio.
| Last Split Date | 6/6/2025 |
| Split Ratio | 30:1 |
Scores
IN8bio, Inc. posts an Altman Z-Score of -9.27, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -9.27 |